Navigation Links
John DeVincenzo, MD, at the University of Tennessee Health Science Center Discovers First Evidence that RNA-interference Drugs Reduce Human Disease
Date:5/28/2010

MEMPHIS, Tenn., May 28 /PRNewswire-USNewswire/ -- John DeVincenzo, MD, professor and researcher in the Departments of Pediatrics and Molecular Sciences at the University of Tennessee Health Science Center (UTHSC), has proven for the first time that a totally new concept in drug design can be used to treat human disease.  Dr. DeVincenzo, who also serves as a children's infectious diseases specialist at Le Bonheur Children's Hospital, conducted his study at the Children's Foundation Research Center, a UT Health Science Center partner located at Le Bonheur.

(Photo: http://www.newscom.com/cgi-bin/prnh/20100528/DC12575 )

(Logo:  http://www.newscom.com/cgi-bin/prnh/20100323/DC75673LOGO )

The new drug design concept is that a simple chain of sugars called RNA (Ribonucleic Acid*) can be easily designed on laptop computers and then synthesized into powerful disease-fighting therapies.  The therapies work by shutting down disease-causing genes through a process known as RNA interference (RNAi).  The discovery of this natural process of RNAi was awarded the Nobel Prize in 2006.  RNAi drugs had shown promise in test tube studies and in animals, but had never been shown to work in humans.  

Realizing the potential power of the new discovery, Dr. DeVincenzo and his team tackled the virus called RSV (Respiratory Syncytial Virus), the most common cause of hospitalization of infants and an infection with no therapy or vaccine.  Healthy adults contract only rare, mild RSV infections that disappear without medical intervention.  The investigator's team infected 88 healthy adults with RSV cultures that he collected and grew from his patients at Le Bonheur Children's Hospital.  He then administered RNAi drug therapy to half the study participants in the form of a nasal spray and a placebo to the other half.  Findings from Dr. DeVincenzo's study proved that the RNAi therapy shut down a gene critical to RSV, thus preventing the virus from replicating itself.  Patients who received the RNAi drug had significantly less infection than those receiving the placebo.  The findings pave the way for this new type of drug therapy to treat a large variety of human diseases including cancers, genetic diseases and viral infections.  In April, the study was published in the Proceedings of the National Academy of Sciences announcing the potential of the RNAi drug therapy.

"The next step in this discovery is already being undertaken," said Dr. DeVincenzo.  "We are in the midst of a clinical trial to test the RNA interference drug in lung-transplant recipients who have become naturally infected with Respiratory Syncytial Virus, which can be deadly for these patients."  The researcher added that the aerosol form of the RNAi drug was proven to be safe in the previous phase of study and the safety is being tested again in the current phase of the clinical trial.  His long-term goal is to test RNAi drug therapies to reduce RSV infections in infants.  

Regarding the possibility of marketing the RNAi drug treatment, Dr. DeVincenzo emphasizes that the drug's commercialization cannot be predicted, but could receive approval as an orphan drug (a treatment for rare conditions) as early as 2013 if the current phase of clinical trials proves to be very successful.  Approval for using RNAi treatment on children who suffer from RSV would take longer.

About the University of Tennessee Health Science Center

As the flagship statewide academic health system, the mission of the University of Tennessee Health Science Center is to bring the benefits of the health sciences to the achievement and maintenance of human health, with a focus on the citizens of Tennessee and the region, by pursuing an integrated program of education, research, clinical care, and public service.  Offering a broad range of postgraduate training opportunities, the main campus is located in Memphis and includes six colleges: Allied Health Sciences, Dentistry, Graduate Health Sciences, Medicine, Nursing and Pharmacy.  UTHSC has additional colleges of Medicine and Pharmacy plus an Allied Health Sciences unit in Knoxville, as well as a College of Medicine campus in Chattanooga.  For more information, visit www.uthsc.edu .

About Le Bonheur Children's Hospital

Founded in 1952, Le Bonheur Children's Hospital is the Mid-South's first and only comprehensive pediatric medical facility.  Every year Le Bonheur treats almost 140,000 children from throughout the U.S. and the world.  Le Bonheur is home to one of the nation's 10 busiest pediatric emergency departments and hosts one of the largest pediatric surgical brain tumor programs.  Le Bonheur is building a new state-of-the art hospital.  The $340-million facility is scheduled to open in 2010 and will significantly increase the space for patient care, research and teaching.  For more information, please call (901) 287-6030 or visit www.lebonheur.org.

About the Children's Foundation Research Center

The Children's Foundation Research Center is a non-profit laboratory-based and clinical research organization created to promote the health of children. The center was created in 1995 by the Children's Foundation of Memphis, the University of Tennessee Health Science Center and Le Bonheur Children's Hospital.  Located at Le Bonheur, it is the home of both basic science laboratories, and clinical and translational research facilities.  It hosts more than 30 pediatric researchers.  For more information, visit www.uthsc.edu/cfrc.

*Ribonucleic Acid (RNA) is one of the two main types of nucleic acid (the other being DNA or deoxyribonucleic acid) which functions in cellular protein synthesis in all living cells and replaces DNA as the carrier of genetic information in some viruses.


'/>"/>
SOURCE University of Tennessee Health Science Center
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Quark Pharmaceuticals Extends Research Agreement with State University of New York for Proprietary siRNA Compounds for Acute Hearing Loss
2. Boston University Biomedical Engineers Find Chink in Bacterias Armor
3. Quark Pharmaceuticals Signs Collaboration Agreement With University of Michigan for Development of Proprietary SiRNA Compounds for Noise-Induced Hearing Loss
4. Potential Breakthrough Cancer Treatment Emerges from MIPS-Funded Clinical Trial Teaming CSA Medical Inc. and University of Maryland Researchers
5. Tezampanel, TorreyPines Therapeutics Lead Compound, Reduced Muscle Spasticity and Rigidity in Preclinical Study Conducted at University of California, San Diego
6. University of Pennsylvania School of Medicine Study Shows Significant Differences in English- and Spanish-speakers Use of Oncology Websites
7. Raydiance Collaborates With Rutgers University and Nations Largest Tissue Bank to Develop Innovative Tissue Processing Approaches
8. Northwest Biotherapeutics Conducting Ovarian Cancer Clinical Trial With DCVax(R)-L at University of Pennsylvania
9. Nobel Laureate Dr. Gunter Blobel to Speak at Florida Atlantic University
10. Beckman Coulter Announces Licensing Agreements for Molecular Tests with National University of Ireland, Galway
11. UM Maryland Industrial Partnerships Program Approves 18 Collaborative Research Projects, Worth $4.4 Million, Between University Faculty, State Technology Companies
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/19/2017)... HORSHAM, Pa. , June 19, 2017  Researchers ... announced today that they will host a live, complimentary ... Perspectives from the benchtop to the real world" on ... PM EDT. This webinar will feature ... a rare look into the manipulation techniques abusers use ...
(Date:6/14/2017)... The Bio Supply Management Alliance (BSMA) has ... and the Biomedical Manufacturing Network to advance ... California by providing a platform for ... workforce development. The primary focus of this alliance is ... well as small and mid-sized biomedical companies. ...
(Date:6/11/2017)... June 10, 2017  Eli Lilly and Company (NYSE: ... Phase 3 studies of galcanezumab, an investigational treatment for ... data on several key secondary endpoints for galcanezumab compared ... these studies (EVOLVE-1, EVOLVE-2 and REGAIN) will be presented ... meeting in Boston . ...
Breaking Medicine Technology:
(Date:6/28/2017)... , ... June 28, 2017 , ... ... management and financial planning assistance to clients in southern Montana, is announcing a ... by Zoo Montana. , The outreach programs offered by Zoo Montana provide students ...
(Date:6/28/2017)... (PRWEB) , ... June 28, 2017 , ... ... consulting firm servicing communities throughout the greater Cincinnati metropolitan area, is teaming up ... temporary lodgings for families with children receiving treatment in nearby hospitals. , Ronald ...
(Date:6/27/2017)... (PRWEB) , ... June 27, 2017 , ... DrugDev ... study is whether they can trust the sponsor to pay them correctly and on ... sponsors and CROs establish payment strategies that encourage sites to work on their studies. ...
(Date:6/27/2017)... ... 2017 , ... The Congressional Budget Office (CBO) projects that the Better Care ... Protection and Affordable Care Act (ACA), would result in 22 million Americans losing their ... , More than 20 million Americans have gained health insurance under the ACA, and ...
(Date:6/27/2017)... ... , ... A January 18th article on medGadget reports that the ... the year 2024 according to a new report. The article also notes that the ... Los Angeles area clinic Beverly Hills Periodontics & Dental Implant Center says that it ...
Breaking Medicine News(10 mins):